A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma
Details
NRG-BN010, A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy In Recurrent Glioblastoma
Eligibility
You can join if...
Inclusion Criteria
-Unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration
Age <18 years.
Karnofsky performance status 70 within 14 days prior to registration
Exclusion Criteria
Diffuse leptomeningeal disease.
Known contrast-enhancing tumor in brainstem or spinal cord. If not previously completed, spinal imaging is not required to determine trial eligibility.
Patients with clinically significant mass effect or midline shift (e.g., 1-2 cm of midline shift)